Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Monday, October 26, 2026

Back to today

How to Read a 10-K Like a Short Seller

A four-layer 10-K framework tests revenue timing, receivables, reserves and depreciation against cash flow, using Hertz’s 2012-14 accounting as a case study.

HTZ $738M
Jimmy's Journal 63 clicks

From X

@StableBread 1 click

Fajasy on X

Boost Run $BRUN said on October 26 that it has closed "more than $600 million in non-dilutive project financing" so far in 2026. In my October 19 update, I said the stock depends less on demand than on whether $BRUN can finance the next ~$1B of GPUs without selling shares at beaten-down prices. The release also says: → $BRUN has established "a fully funded runway to accelerate customer deployments through the fourth quarter of 2026," with additional financing "proceeding as planned." → $BRUN delivered the first phase of a multi-phase project to "a leading AI research and product company," which matches its $471.7M May 2026 contract with Thinking Machines Lab (Mira Murati's AI startup). → Several more projects are "nearing hand-off in the coming weeks." → Founder and CEO Andrew Karos: "Customer payments exceed our debt payments every month." The $600M+ is YTD, and lessors funded $268.3M of new GPU leases in H1 2026 alone. So if those leases count toward the $600M+, $BRUN has closed more than $331.7M since June 30, about half to almost two-thirds of the $527-686M of new leases I estimated its H2 2026 build needs. The release doesn't say what the financing costs or how much of it closed since June 30. However, the Q3 10-Q, expected in mid-November, should disclose how much $BRUN leased in Q3 and at what rate. If the 10-Q confirms the $600M+, I'd drop the $62.2M stock sale from my bear case, and the question shifts from whether $BRUN can fund its build to what the new debt costs.
@KEDM_COM

KEDM.com on X

Merion Road and Blue Hill are going activist at United Bancorporation of Alabama $UBAB, looking for board seats. They see UBAB at a key moment, needing better capital allocation, tighter expenses, and a clearer strategy. Still, the board hasn't acted on their proposals despite years of engagement. They're also looking for a $40m tender (~17% of the market cap). These guys hold just 2%, so UBAB basically replied, 'yeah, that's not going to happen,' but this ECIP winner could indeed do more.

Investor Letters

All letters

Namib Minerals: Research Flash

Namib Minerals’ How Mine mill reached 55,000 tonnes per month, 36% above prior capacity, while a proposed $30 million Ecobank facility…

NAMM $48M
Atrium Research - Equity Research 2 clicks

Bimergen Energy: Research Flash

Bimergen Energy filed for a Texas retail-power license to supply data centers directly and gained eligibility for federal contracts through…

BESS $13M
Atrium Research - Equity Research 3 clicks

Unicycive (UNCY):

Unicycive’s oxylanthanum carbonate NDA earned a March 25, 2027 PDUFA date after two manufacturing-related rejections, with no FDA clinical…

UNCY $98M
Triple S Special Situations Investing 4 clicks

Moon River Moly: Research Note

Moon River Moly’s updated Davidson PEA lifts after-tax NPV to $1.24 billion as flotation raises tungsten output 350% and cuts molybdenum…

MRIVF $23M
Atrium Research - Equity Research 4 clicks

GLOO, part two

Gloo faces related-party deals, insider-heavy IPO ownership, acquisition losses and $84.5 million of CEO-backed puts as it burns cash and…

GLOO $269M
Guardian Research 4 clicks

Carecloud News

CareCloud may attract a private-equity buyer after its Q3 call, with acquiring enough shares the main obstacle to a take-private deal.

CCLD $74M
Calvin Blissett 11 clicks
OPRX · long

Optimizerx CORP

OptimizeRx, OPRX, trades 30% below its February 2025 writeup despite becoming a stronger company.

OPRX $172M
Value Investors Club 2 clicks

CYD and H22 Results First Take:

CYD’s FY24 earnings miss reflected ¥200m of one-offs; adjusted net income reached roughly ¥430m and operating cash flow rose 40%.

CYD $956M
Maius Partners 2 clicks

Portfolio Updates

CYD was sold near $21 versus an $11 entry after exceeding a $19.50 target; proceeds moved to H22.SI, whose CYD stake implies $1.30 NAV and…

CYD $956M
Maius Partners 4 clicks

Fading a Myopic Sell-Off

Organigram’s shares fell 25% after Q1, despite Motif Labs making OGI Canada’s largest cannabis producer and a top-three player across major…

OGI $132M
Raging Bull Investments 1 click

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 62 of 256

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

190 firms

Sectors

Ordered by how often our editor reaches for them.